At a glance
ClinicalIndex Comparison Record- ✓Histologically or cytologically confirmed advanced ovarian epithelial, primary peritoneal cavity, or fallopian tube cancer (Phase I and II) or metastatic breast cancer (Phase I only)
- ✓Platinum- and taxane-resistant disease with disease-free interval <6 months after completion of platinum- and taxane-based chemotherapy, or disease progression during the regimen (Phase II), or ≥2 prior regimens for metastatic breast cancer including 1 taxane-based regimen (Phase I)
- ✓Measurable or evaluable disease: unidimensionally measurable lesion, or CA 125 >50 U/mL on 2 occasions ≥1 week apart, or CA 27-29, CA 15-3, or CA 125 >50 U/mL on 2 occasions ≥1 week apart (breast cancer)
- ✓Life expectancy >3 months
- ✕Grade ≥2 neuropathy
- ✕Active brain metastases with evidence of cerebral edema, disease progression on prior imaging, requirement for steroids, or clinical symptoms
- ✕Symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia
- ✕Ongoing or active infection
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I/II Study of BMS-247550 and Pegylated Liposomal Doxorubicin (Doxil®) in Patients With Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer Who Have Been Previously Treated With a Platinum and a Taxane
In Brief
A Phase 2 clinical trial evaluating ixabepilone and pegylated liposomal doxorubicin hydrochloride for Fallopian Tube Cancer and 6 related conditions. Completed, enrolled 45 participants across 5 sites.
Detailed Summary
This trial is studying the side effects and best dose of ixabepilone when given together with pegylated liposomal doxorubicin hydrochloride and to see how well they work in treating women with advanced ovarian epithelial, primary peritoneal cavity, or fallopian tube cancer or metastatic breast cancer. Drugs used in chemotherapy, such as ixabepilone and pegylated liposomal doxorubicin hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells.
Study Details
Timeline
Interventions
Given IV
Given IV